| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (groß) | News + Adhoc | Bilanz/GuV | Termine | Zertifikate | Depot |
| Times + Sales | Chart-Analyse | Analysen | Dividende/HV | Profil | Optionsscheine | Watchlist |
| Börsenplätze | Chartvergleich | Kursziele | Insidertrades | Knock-outs | myfinanzen | |
| Orderbuch | Realtime Stuttgart | RSS Feed | im Forum | Fonds | Senden/Drucken | |
| Historisch | Realtime Push | IR-Daten | Anleihen | handeln | ||
08.02.12 | Ligand Pharmaceuticals Crushes Estimates (EN, MotleyFool) |
14.11.11 | Edison Investment Research Expects Growth for Ligand Pharmaceuticals (EN, Benzinga earnings) |
09.02.12 | Ligand to Present at the BIO CEO and Investor Conference on February 13 (Businesswire) |
08.02.12 | Ligand Pharmaceuticals Crushes Estimates (EN, MotleyFool) |
07.02.12 | Ligand Reports Fourth Quarter and Full Year 2011 Financial Results (Businesswire) |
07.02.12 | Ligand Names Nishan de Silva, M.D., Vice President of Corporate Development (Businesswire) |
02.02.12 | Ligand Presents Full Data from Successful Phase II Trial of Captisol-Enabled®, Propylene Glycol-Free Melphalan at the BMT Tandem Meetings (Businesswire) |
01.02.12 | Ligand to Report Fourth Quarter Results on February 7 (Businesswire) |
04.01.12 | Ligand to Present at the Biotech Showcase Conference on January 10th (Businesswire) |
21.12.11 | Ligand Enters into Platform Captisol® License and Supply Agreements with Lilly (Businesswire) |
09.02.12 | Ligand to Present at the BIO CEO and Investor Conference on February 13 (Businesswire) |
07.02.12 | Ligand Reports Fourth Quarter and Full Year 2011 Financial Results (Businesswire) |
07.02.12 | Ligand Names Nishan de Silva, M.D., Vice President of Corporate Development (Businesswire) |
02.02.12 | Ligand Presents Full Data from Successful Phase II Trial of Captisol-Enabled®, Propylene Glycol-Free Melphalan at the BMT Tandem Meetings (Businesswire) |
01.02.12 | Ligand to Report Fourth Quarter Results on February 7 (Businesswire) |
04.01.12 | Ligand to Present at the Biotech Showcase Conference on January 10th (Businesswire) |
21.12.11 | Ligand Enters into Platform Captisol® License and Supply Agreements with Lilly (Businesswire) |
12.12.11 | Ligand Announces Positive Preclinical Data on Small-Molecule GCSF Receptor Agonist at the 53rd Annual Meeting of the American Society of Hematology (Businesswire) |
| Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv |
08.02.12 | Ligand Pharmaceuticals Crushes Estimates (EN, MotleyFool) |
14.11.11 | Edison Investment Research Expects Growth for Ligand Pharmaceuticals (EN, Benzinga earnings) |
| Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv |
09.02.12 | Ligand to Present at the BIO CEO and Investor Conference on February 13 (Businesswire) |
08.02.12 | Ligand Pharmaceuticals Crushes Estimates (EN, MotleyFool) |
07.02.12 | Ligand Reports Fourth Quarter and Full Year 2011 Financial Results (Businesswire) |
07.02.12 | Ligand Names Nishan de Silva, M.D., Vice President of Corporate Development (Businesswire) |
02.02.12 | Ligand Presents Full Data from Successful Phase II Trial of Captisol-Enabled®, Propylene Glycol-Free Melphalan at the BMT Tandem Meetings (Businesswire) |
01.02.12 | Ligand to Report Fourth Quarter Results on February 7 (Businesswire) |
04.01.12 | Ligand to Present at the Biotech Showcase Conference on January 10th (Businesswire) |
21.12.11 | Ligand Enters into Platform Captisol® License and Supply Agreements with Lilly (Businesswire) |
| Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv |
09.02.12 | Ligand to Present at the BIO CEO and Investor Conference on February 13 (Businesswire) |
07.02.12 | Ligand Reports Fourth Quarter and Full Year 2011 Financial Results (Businesswire) |
07.02.12 | Ligand Names Nishan de Silva, M.D., Vice President of Corporate Development (Businesswire) |
02.02.12 | Ligand Presents Full Data from Successful Phase II Trial of Captisol-Enabled®, Propylene Glycol-Free Melphalan at the BMT Tandem Meetings (Businesswire) |
01.02.12 | Ligand to Report Fourth Quarter Results on February 7 (Businesswire) |
04.01.12 | Ligand to Present at the Biotech Showcase Conference on January 10th (Businesswire) |
21.12.11 | Ligand Enters into Platform Captisol® License and Supply Agreements with Lilly (Businesswire) |
12.12.11 | Ligand Announces Positive Preclinical Data on Small-Molecule GCSF Receptor Agonist at the 53rd Annual Meeting of the American Society of Hematology (Businesswire) |
| Keine Nachrichten im Zeitraum eines Monats in dieser Kategorie verfügbar |
02.02.12 | Ligand Presents Full Data from Successful Phase II Trial of Captisol-Enabled®, Propylene Glycol-Free Melphalan at the BMT Tandem Meetings (Businesswire) |
07.02.12 | Ligand Reports Fourth Quarter and Full Year 2011 Financial Results (Businesswire) |
09.02.12 | Ligand to Present at the BIO CEO and Investor Conference on February 13 (Businesswire) |
01.02.12 | Ligand to Report Fourth Quarter Results on February 7 (Businesswire) |
07.02.12 | Ligand Names Nishan de Silva, M.D., Vice President of Corporate Development (Businesswire) |
08.02.12 | Ligand Pharmaceuticals Crushes Estimates (EN, MotleyFool) |
| Keine Nachrichten im Zeitraum eines Monats in dieser Kategorie verfügbar |
02.02.12 | Ligand Presents Full Data from Successful Phase II Trial of Captisol-Enabled®, Propylene Glycol-Free Melphalan at the BMT Tandem Meetings (Businesswire) |
07.02.12 | Ligand Reports Fourth Quarter and Full Year 2011 Financial Results (Businesswire) |
09.02.12 | Ligand to Present at the BIO CEO and Investor Conference on February 13 (Businesswire) |
01.02.12 | Ligand to Report Fourth Quarter Results on February 7 (Businesswire) |
07.02.12 | Ligand Names Nishan de Silva, M.D., Vice President of Corporate Development (Businesswire) |
08.02.12 | Ligand Pharmaceuticals Crushes Estimates (EN, MotleyFool) |
02.02.12 | Ligand Presents Full Data from Successful Phase II Trial of Captisol-Enabled®, Propylene Glycol-Free Melphalan at the BMT Tandem Meetings (Businesswire) |
07.02.12 | Ligand Reports Fourth Quarter and Full Year 2011 Financial Results (Businesswire) |
09.02.12 | Ligand to Present at the BIO CEO and Investor Conference on February 13 (Businesswire) |
01.02.12 | Ligand to Report Fourth Quarter Results on February 7 (Businesswire) |
07.02.12 | Ligand Names Nishan de Silva, M.D., Vice President of Corporate Development (Businesswire) |
| Keine Nachrichten im Zeitraum eines Monats in dieser Kategorie verfügbar |
02.02.12 | Ligand Presents Full Data from Successful Phase II Trial of Captisol-Enabled®, Propylene Glycol-Free Melphalan at the BMT Tandem Meetings (Businesswire) |
07.02.12 | Ligand Reports Fourth Quarter and Full Year 2011 Financial Results (Businesswire) |
09.02.12 | Ligand to Present at the BIO CEO and Investor Conference on February 13 (Businesswire) |
01.02.12 | Ligand to Report Fourth Quarter Results on February 7 (Businesswire) |
07.02.12 | Ligand Names Nishan de Silva, M.D., Vice President of Corporate Development (Businesswire) |
| 06.07.10 | Ligand Pharmaceuticals Talfahrt sollte vorbei sein | Global Biotech Investing | |
| 05.08.09 | Ligand Pharmaceuticals Downgrade | Merriman Curhan Ford & Co | |
| 22.01.09 | Ligand Pharmaceuticals Ersteinschätzung | Oppenheimer & Co. Inc. | |
| 27.11.08 | Ligand Pharmaceuticals market outperform | Rodman & Renshaw, LLC | |
| 29.05.08 | Ligand Pharmaceuticals neues Kursziel | Susquehanna Financial Group, LLLP |
| 06.07.10 | Ligand Pharmaceuticals Talfahrt sollte vorbei sein | Global Biotech Investing | |
| 22.01.09 | Ligand Pharmaceuticals Ersteinschätzung | Oppenheimer & Co. Inc. | |
| 27.11.08 | Ligand Pharmaceuticals market outperform | Rodman & Renshaw, LLC | |
| 29.05.08 | Ligand Pharmaceuticals neues Kursziel | Susquehanna Financial Group, LLLP | |
| 07.12.07 | Ligand Pharmaceuticals positive | Susquehanna Financial Group, LLLP |
| 05.08.09 | Ligand Pharmaceuticals Downgrade | Merriman Curhan Ford & Co | |
| 21.03.06 | Update Ligand Pharmaceuticals Inc.: Neutral | First Albany | |
| 17.03.06 | Ligand Pharmaceuticals Downgrade | First Albany | |
| 19.01.06 | Ligand Pharmaceuticals Upgrade | Evern Securities | |
| 18.01.06 | Update Ligand Pharmaceuticals Inc.: Market Perform | Friedman, Billings Ramsey & Co |
| Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv |
| Marktkapitalisierung in Mio. EUR | 219,13 |
| WKN | 895777 |
| ISIN | US53220K2078 |
| Deutsches Symbol | LGD |
| Ausländisches Symbol | LGND |
| Indizes | NASDAQ Composite Index |
| Land | USA |
| Branchen | Biotech |
| getgoods | +795,5% | |
| Mania Technologie | +456,3% | |
| ARQUANA International PrintMedia | +435,7% | |
| emQtec | +375,0% | |
| CPU Softwarehouse | +363,3% |